Nitric Oxide Metabolites and Lung Cancer Incidence: A Matched Case-Control Study Nested in the ESTHER Cohort

Abstract EN

Studies suggest that nitric oxide (NO) may have a possible role in lung carcinogenesis.

This study is aimed to evaluate the association of the NO metabolites, namely, nitrite and nitrate, with lung cancer incidence.

We conducted a matched case-control study (n=245 incident lung cancer cases and n=735 controls) based on the German ESTHER cohort (n=9,940).

Controls were matched to cases on age, sex, smoking status (never/former/current smoking), and pack-years of smoking.

The sum of nitrite and nitrate was measured in urine samples using a colorimetric assay and was standardized for renal function by urinary creatinine.

Conditional logistic regression models, adjusted for lifestyle factors, asthma prevalence, and family history of lung cancer, were used to estimate odds ratios (ORs) and 95% confidence intervals (95% CI).

Among incident lung cancer cases, high nitrite/nitrate levels were statistically significantly associated with current smoking, a low BMI, and the oxidative stress biomarker 8-isoprostane levels.

Nitrite/nitrate levels in the top quintile were statistically significantly associated with lung cancer incidence: the OR (95% CI) was 1.37 (1.04-1.82) for comparison with the bottom quintile.

This association was unaltered after additional adjustment for 8-isoprostane levels and C-reactive protein (CRP).

In conclusion, this large cohort study suggested that subjects with high urinary nitrite/nitrate concentrations had an increased risk of lung cancer and this association was independent of smoking, CRP, 8-isoprostane levels, and other established lung cancer risk factors.

Further studies are needed to validate these findings and to confirm the hypothesis that pathologically high levels of NO are involved in lung cancer development.